VERVE-102

Phase 1Small molecule

VVerve Therapeutics, Inc.

VERVE-102 is one of 6 small molecule programs targeting Familial Hypercholesterolemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Familial HypercholesterolemiaRecruiting

Familial HypercholesterolemiaPhase 1

Recruiting

Competition

Competitive Landscape

7 competitors in Familial Hypercholesterolemia

#DrugCompanyPhaseTrials

Niacor

Leqvio

4 3

QLC7401

Qilu Pharmaceutical Co., Ltd.

Phase 3

2 4

Atorvastatin Calcium

YOLT-101

2 6

VERVE-102

VVerve Therapeutics, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Familial Hypercholesterolemia

NCT06164730

Clinical

Trials by Indication[1]

Familial Hypercholesterolemia1 trial

Open-label, Phase 1b, Single Ascending Dose Study to Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia or Premature Coronary Artery Disease Who Require Additional Lowering of Low-density Lipoprotein Cholesterol

Recruiting·VVerve Therapeutics, Inc.·Phase 1·NCT06164730·85 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for VERVE-102. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VERVE-102 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VERVE-102. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Verve Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: VVerve Therapeutics, Inc.

VERVE-102

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Familial Hypercholesterolemia1 trial

References

Drug Info

Quick Facts

Related News